New Forecasts: Here's What One Analyst Thinks The Future Holds For Grand Venture Technology Limited (SGX:JLB)
Shareholders in Grand Venture Technology Limited (SGX:JLB) may be thrilled to learn that the covering analyst has just delivered a major upgrade to their near-term forecasts. The revenue forecast for this year has experienced a facelift, with the analyst now much more optimistic on its sales pipeline.
Following the upgrade, the most recent consensus for Grand Venture Technology from its one analyst is for revenues of S$194m in 2025 which, if met, would be a major 22% increase on its sales over the past 12 months. Per-share earnings are expected to jump 34% to S$0.043. Prior to this update, the analyst had been forecasting revenues of S$175m and earnings per share (EPS) of S$0.04 in 2025. The forecasts seem more optimistic now, with a decent improvement in revenue and a modest lift to earnings per share estimates.
View our latest analysis for Grand Venture Technology
It will come as no surprise to learn that the analyst has increased their price target for Grand Venture Technology 7.7% to S$1.12 on the back of these upgrades.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Grand Venture Technology's past performance and to peers in the same industry. The period to the end of 2025 brings more of the same, according to the analyst, with revenue forecast to display 22% growth on an annualised basis. That is in line with its 19% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 10% per year. So it's pretty clear that Grand Venture Technology is forecast to grow substantially faster than its industry.
The Bottom Line
The biggest takeaway for us from these new estimates is that the analyst upgraded their earnings per share estimates, with improved earnings power expected for this year. Fortunately, the analyst also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. There was also a nice increase in the price target, with the analyst apparently feeling that the intrinsic value of the business is improving. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Grand Venture Technology.
Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have analyst estimates for Grand Venture Technology going out as far as 2026, and you can see them free on our platform here.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SGX:JLB
Grand Venture Technology
Offers precision manufacturing solutions for the semiconductor, life sciences, electronics, aerospace, and medical industries in Singapore, Malaysia, the United States, China, and internationally.
Solid track record with reasonable growth potential.
Market Insights
Community Narratives


